Novartis builds study on Apple ResearchKit to investigate multiple sclerosis

Jessica Kim Cohen - Print  | 

Basel, Switzerland-based pharmaceutical company Novartis and Seattle-based research nonprofit Sage Bionetworks initiated a large-scale study on multiple sclerosis using the Apple ResearchKit software framework Aug. 21.

The study — called "Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis," or elevateMS — uses a mobile app built on ResearchKit, a smartphone platform that helps medical researchers gather data and enroll participants.

With the smartphone app, researchers can collect sensor-based movement data and questionnaire responses from participants without the need for clinic visits. Participants will be able to view their data on the app to learn how their trends change over time.

The goal of the study is to improve understanding of the challenges people with multiple sclerosis face on a daily basis. The researchers also hope to inform additional measures of treatment effectiveness.

"As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe," said Stanley Cohan, MD, PhD, medical director of Portland-based Providence Multiple Sclerosis Center and a scientific advisor for the study. "This data may provide researchers with new ways to look at disease progression and treatment effectiveness."

More articles on data analytics & precision medicine:
IBM, JDRF use AI to research Type 1 diabetes onset in children
MAP Health Management taps Wolters Kluwer Health for data exchange services
NIH provides up to $14.8M for pediatric data resource center

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.